Company intelligence
Curi Bio
Human Data for Next Generation Medicines
About Curi Bio
"Human Data for Next Generation Medicines" Curi Bio unlocks novel workflows and critical human data to inform R&D decision-making. Through an integrated platform featuring advanced 3D tissue models of disease, biosystems enabling clinically relevant functional analyses, and AI/ML-enabled insights, Curi Bio merges functional and analytical assessments for drug safety, efficacy, and potency
Verified activity
Signals from Curi Bio
10 published signals
People
Curi Bio is hiring a Regional Sales Manager to own and grow the US West territory.
Reported by Curi Bio
Research & Knowledge
Curi Bio is submitting a new Frontiers-Pharmacology, Toxicology and Drugs Research Topic titled Organoids and New Approach Methodologies in Drug Discovery: From Target to Industry for submissions.
Reported by Curi Bio
People
Curi Bio is hiring a Regional Sales Manager for the West Coast team.
Reported by Heejoon Choi
Research & Knowledge
Curi Bio is soliciting contributions for a special issue of Frontiers-Pharmacology, Toxicology and Drugs titled Organoids and New Approach Methodologies in Drug Discovery: From Target to Industry.
Reported by Nicholas Geisse
Research & Knowledge
Curi Bio builds human iPSC-derived engineered muscle tissues from isogenic control and dystrophin-null DMD myoblasts using the Mantarray platform to measure contractile force, contraction and relaxation kinetics, and fatigue under repeated stimulation.
Reported by Curi Bio
Presence & Recognition
Curi Bio's Director of Business Development, Europe, Dr. Hamed Ghazizadeh is attending the 53rd European Muscle Conference in Vienna, Austria from September 6-9.
Reported by Curi Bio
Research & Knowledge
Curi Bio published longitudinal transgene expression data of characterizing capsid transduction efficiency in 96 human iPSC-derived engineered skeletal muscle tissues and a panel of in vivo validated myotropic AAV capsids from Dyno Therapeutics.
Reported by Curi Bio
Presence & Recognition
Curi Bio is presenting AAV capsid screening data at a webinar with Dyno Therapeutics on Wednesday, September 23 at 8 AM PT.
Reported by Curi Bio
Research & Knowledge
Curi Bio used its 3D human iPSC-derived neuromuscular junction model on Mantarray™ to run an exercise protocol optimized by machine learning and measure contractility through the synapse itself via optogenetic activation of motor neurons expressing ChR2.
Reported by Curi Bio
Research & Knowledge
Curi Bio added motor neuron organoids and push button ML-generated exercise protocols to dramatically improve muscle function
Reported by Greg Luerman